三阴乳腺癌化疗的研究进展  

Research development of triple-negative breast cancer chemotherapy

作　　者：章国晶[1] 谢晓冬[1] 

机构地区：[1]沈阳军区总医院肿瘤科,110840

出　　处：《国际肿瘤学杂志》2012年第1期27-31,共5页Journal of International Oncology

基　　金：基金项目：辽宁省自然科学基金资助项目（20082070）

摘　　要：三阴乳腺癌（TNBC）因浸润性较强是乳腺癌中预后不佳的一种亚型，其治疗已受到广泛关注，但尚无明确的标准。TNBC在新辅助化疗中可获得12％-48％的病理完全反应率（pCR），高于其他类型乳腺癌，但其pCR在文献报道中波动幅度较大。辅助化疗在早期TNBC中的应用仍存在争议，有学者主张使用不含蒽环类药物的化疗方案。紫杉类、蒽环类等细胞毒性药物仍是Et前TNBC解救化疗的主力药物，临床试验显示，联合应用吉西他滨或卡培他滨可延长患者生存期。ADP．核糖聚合酶（PARP）成为TNBC靶向治疗新的研究靶点，对其抑制剂如BSI-201和Olaparib的深入研究有望为临床治疗提供更多有效的选择。Triple-negative breast cancer （TNBC）is a subtype of breast cancer, and it is characterized by an aggressive clinical course with a poor prognosis. Treatment for TNBC has attracted much attention in recent years, however, there is no standard treatment for TNBC in clinical setting. The pCR rates of neoadjuvant chemotherapy in TNBC ranges from 12% to 48% in the current published data, and it is higher than that in other types of breast cancer, however, the fluctuating range of the TNBC ＇s pCR is large in literature. Although the administration of adjuvant chemotherapy for early TNBC is controversial, the regimen without anthracyclines is reported to be suitable for early TNBC patients. Standard cytotoxic agents including taxanes and anthracyclines are still the main choices for TNBC salvage treatment, and the combination with gemcitabine or capecitabine may improve the overall survival. Poly （ADP-ribose） polymerase （PARP） is a new molecular target for TNBC in ongoing studies. Further research on the target-inhibitors such as BSI-201and Olaparib will provide more effective choices to clinical treatment.

关 键 词：三阴乳腺癌 药物疗法 靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]